Eurasian Journal of Toxicology

Yazarlar: Sertaç GÜLER, Dilber ÜÇÖZ KOCAŞABAN

Konular:Toksikoloji, Acil Tıp

Anahtar Kelimeler:Emergency medicine,Suicide,Ticagrelor,Intoxication

Özet: Ticagrelor is one of the new generation antiplatelet agents, which acts by reversibly binding to P2Y12 platelet receptors. Literature-related data on overdose intake of ticagrelor is quite limited. Here, we report a 23-year old male patient, who presented to our emergency clinic (ER) with the complaint of suicidal intake of 15 tablets of 90 mg ticagrelor (Brilinta® 90 mg tablet, Astra Zeneca Pharmaceuticals, Istanbul). Ticagrelor is one of the new generation antiplatelet agents that is currently being used in the treatment of acute coronary syndrome in our country. The overdose use of the drug for suicidal purpose or accidentally, is a relatively new issue for ER physicians. According to our knowledge, suicidal ticagrelor overdose intake is a case that has not been reported in the literature previously. In this article, we shared the asymptomatic process of a case with 1350 mg ticagrelor toxicity. With the increased use and prevalence of the drug in our country, we think that the ER physicians may encounter ticagrelor poisoning at higher rates. Therefore, in ticagrelor poisoning, ER physicians need to be aware and familiar with the drug.

---